SXTP vs DRMA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

SXTP

55.9
AI Score
VS
SXTP Wins

DRMA

36.9
AI Score

Investment Advisor Scores

SXTP

56score
Recommendation
HOLD

DRMA

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric SXTP DRMA Winner
Net Income -7.37M -4.81M DRMA
Operating Income -7.76M -4.94M DRMA
ROE -212.7% -138.0% DRMA
ROA -137.3% -90.5% DRMA
Total Assets 5.37M 5.32M SXTP
Cash 1.51M 4.41M DRMA
Current Ratio 2.66 3.40 DRMA
Free Cash Flow -6.99M -5.01M DRMA

Relative Price Performance (Last 90 Days)

SXTP 1M: -24.2% · 3M: -24.2% DRMA 1M: +12.7% · 3M: +14.5%

Current Technical Phase

SXTP

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 37

RSI (14): 36.7 · Price: $1.13

DRMA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 57

RSI (14): 57.1 · Price: $1.42

Fundamentals Snapshot

Metric SXTP DRMA
Market Cap
Forward P/E -0.3 -1.0
Trailing P/E
Revenue (TTM)
Revenue Growth -0.3% 0.0%
Gross Margin -1.0%
Operating Margin -10.9% 0.0%
EPS -6.76 -4.20
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, SXTP is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.